Article
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
PloS one - 27 May 2009
Jaiswal Bijay S, Janakiraman Vasantharajan, Kljavin Noelyn M, Eastham-Anderson Jeffrey, Cupp James E, Liang Yuxin, Davis David P, Hoeflich Klaus P, Seshagiri Somasekar
Abstract excerpt
BACKGROUND: Oncogenic RAS is a highly validated cancer target. Attempts at targeting RAS directly have so far not succeeded in the clinic. Understanding downstream RAS-effectors that mediate oncogenesis in a RAS mutant setting will help tailor treatments that use RAS-effector inhibitors either alone or in combination to target RAS-driven tumors. METHODOLOGY/PRINCIPAL FINDINGS: In this study, we have investigated...
Topics
- Animals
- Cell Adhesion
- Cell Cycle
- Cell Line, Tumor
- Cell Proliferation
- Gene Knockdown Techniques
- Humans
- Mice
- Mutant Proteins
- Mutation
- Neoplasms